EJPMR, 2026, 13(2), 35-41 **Review Article** **Impact Factor 7.065**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

METHOD DEVELOPMENT AND VALIDATION OF ANTIBIOTICS BY RP-HPLC WITH EMPHASIS ON STABILITY STUDIES: A COMPREHENSIVE REVIEW

Md. Saniya[1], Sreelatha Gangu[1]*, Mallani Sirisha[1], Sarvepalli Gnana Samanvitha[1], Shaik Naziya Fathima[1], Arunabha Mallik[2]

[1]Department of Pharmaceutical Analysis, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India.
[2]Department of Pharmacology, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana – 500046, India.

***Corresponding Author: Sreelatha Gangu**

Department of Pharmaceutical Analysis, Marri Laxman Reddy Institute of Pharmacy, Dundigal, Hyderabad, Telangana - 500046, India. **DOI:** https://doi.org/10.5281/zenodo.18428622

How to cite this Article: Md. Saniya1, Sreelatha Gangu1*, Mallani Sirisha1, Sarvepalli Gnana Samanvitha1, Shaik Naziya Fathima1, Arunabha Mallik2. (2026). Method Development and Validation of Antibiotics By Rp-Hplc with Emphasis on Stability Studies: A Comprehensive Review. European Journal of Pharmaceutical and Medical Research, 13(2), 35–41.

Article Received on 05/01/2026 **Article Revised on 25/01/2026** **Article Published on 01/02/2026**

ABSTRACT

Antibiotics remain a cornerstone of global healthcare, yet increasing antimicrobial resistance and strict quality-control requirements necessitate highly accurate and robust analytical methods for their quantification. Reversed-phase high-performance liquid chromatography (RP-HPLC) is the most widely used analytical technique for the routine and stability-indicating analysis of antibiotic drug substances and formulations. This review provides a comprehensive overview of RP-HPLC method development strategies, validation requirements and forced degradation studies specific to antibiotics. It examines a wide range of chromatographic conditions applied to β-lactams, macrolides, fluoroquinolones, cephalosporins, tetracyclines and aminoglycosides. A systematic literature review summarizes major analytical methods reported in the last two decades, highlighting chromatographic challenges, degradation pathways, impurity profiling and method robustness considerations. Emerging analytical trends such as green chromatography, Quality by Design (QbD) and hyphenated techniques (PDA/MS) are also discussed. The review emphasizes the need for stability-indicating analytical methods to comply with ICH regulations and ensure the safety, efficacy and shelf life of antibiotic formulations.

KEYWORDS: RP-HPLC, Antibiotics, Method Development, Validation, Stability-Indicating Methods, Forced Degradation, ICH Q1A(R2), ICH Q2(R2), impurity profiling, QbD.

1. INTRODUCTION

Antibiotics represent one of the most crucial therapeutic categories for treating infectious diseases. With the expansion of multi-drug resistant (MDR) pathogens and increased pharmaceutical manufacturing, the demand for robust analytical quality control methods has grown significantly.[1] Antibiotic drug substances and formulations often display complex chemical behaviors such as hydrolysis, oxidation, epimerization, β-lactam ring cleavage and pH-dependent degradation. Hence, stability-indicating RP-HPLC methods have become essential for ensuring product integrity, therapeutic outcome and regulatory compliance.

RP-HPLC is highly preferred due to its reproducibility, selectivity, versatility and ability to quantify drugs in the presence of degradation products, excipients and impurities. Many antibiotics—including Penicillins, Cephalosporins, Macrolides, Fluoroquinolones, Sulfonamides and Carbapenems—require specialized chromatographic conditions due to their polarity, unstable functional groups and multicomponent formulations.[2]

The International Council for Harmonisation (ICH) mandates stability studies for all pharmaceutical products (ICH Q1A (R2)) and validation of analytical procedures (ICH Q2 (R2)). Consequently, analytical scientists must carefully design methods that provide separation

between the active pharmaceutical ingredient (API) and its degradation products, ensuring accuracy across the product shelf life.[3]

This review provides a detailed and structured evaluation of RP-HPLC methods reported for antibiotics, emphasizing stability studies, forced degradation, method development and critical validation parameters.[4]

2. REVIEW OF LITERATURE

The literature on antibiotic quantification using RP-HPLC is extensive. Table 1 summarizes key studies for major antibiotic classes.[12-24]

Table 1: Summary of Important Stability-Indicating RP-HPLC Methods for Antibiotics.

Antibiotic Class	Representative Drugs	Stationary Phase	Mobile Phase	Detection λ (nm)	Key Findings
β-Lactams	Amoxicillin, Ampicillin, Cloxacillin	C18	Water: Acetonitrile or Buffer: Acetonitrile	220–254 nm	Degrade rapidly in alkaline pH; stability-indicating methods essential
Cephalosporins	Cefixime, Cefpodoxime, Ceftriaxone	C18	Phosphate buffer + Acetonitrile /MeOH	230–280 nm	Sensitive to heat & light; multiple degradation peaks observed
Macrolides	Azithromycin, Erythromycin	C8/C18	Methanol-rich mobile phase	210–215 nm	Require ion-pairing agents for better peak shape
Fluoroquinolones	Ciprofloxacin, Levofloxacin, Moxifloxacin	C18	Acidic Buffer + Acetonitrile	278–295 nm	Strong chromophores allow good sensitivity
Tetracyclines	Doxycycline, Tetracycline	C18	Oxalic acid buffer + MeOH	270–280 nm	Sensitive to oxidation & epimerization
Aminoglycosides	Gentamicin, Amikacin	HILIC/C18	Ion-Pair Chromatography	195–215 nm	Lack chromophores; need derivatization or UV modifiers

3. METHOD DEVELOPMENT STRATEGIES FOR ANTIBIOTICS

RP-HPLC method development involves optimizing several chromatographic parameters[5-8]

3.1 Selection of Stationary Phase

Most antibiotic methods require

* C18 columns (commonly used)
* C8 columns (for macrolides & lipid-soluble antibiotics)
* Phenyl columns (for aromatic antibiotics)
* HILIC columns (for aminoglycosides)

Key considerations

* Stability of column packing
* Silanol activity
* End-capping for peak symmetry

3.2 Mobile Phase Optimization[9]

Antibiotics typically require:

* Buffered phases (pH 2.5–4.5)
* ACN or methanol as organic modifiers
* Ion-pair reagents (heptane sulfonate, triethylamine)

Critical parameters

* pH affects ionization and retention
* Buffer strength influences peak shape
* Organic phase ratio adjusts resolution

3.3 General Steps for RP-HPLC Method Development[10]

METHOD DEVELOPMENT WORKFLOW



Fig. 1: Workflow of Method Development.

1. Understand drug structure → identify functional groups & pKa
2. Select stationary phase (C18 preferred)
3. Choose mobile phase components (Buffer + ACN/MeOH)
4. Adjust pH based on ionizable groups
5. Optimize retention time (3–10 min ideal)
6. Achieve baseline separation from impurities
7. Test forced degradation samples → evaluate stability-indicating nature
8. Validate according to ICH Q2 (R2)

4. STABILITY STUDIES AND FORCED DEGRADATION

Stability-indicating methods are mandatory to differentiate API from degradation products.[11-13]

4.1 ICH-recommended stress conditions

* Acid hydrolysis: 0.1N HCl
* Base hydrolysis: 0.1N NaOH
* Oxidation: 3–10% H_2O_2
* Thermal stress: 60–80°C
* Photolysis: UV/fluorescent exposure
* Humidity stress: 75% RH

4.2 Common degradation pathways in antibiotics

* β-lactam ring opening in Penicillins & Cephalosporins
* Ester cleavage in macrolides
* Epimerization in tetracyclines
* Oxidation in fluoroquinolones
* Aminoglycosides degrade under acidic conditions

A proper method must resolve all degradants with acceptable peak purity (PDA-based).[14]

5. METHOD VALIDATION (ICH Q2(R2))

Parameters[15-18]

* System suitability
* Linearity
* Precision (repeatability, intermediate)
* Accuracy (% recovery)
* Specificity
* LOD/LOQ
* Robustness
* Ruggedness
* Solution stability

Acceptance Criteria

* Correlation coefficient (R^2): ≥ 0.999
* %RSD (precision): ≤ 2%
* Recovery: 98–102%
* Resolution: > 2

6. DISCUSSION

The development and validation of RP-HPLC methods for antibiotics have evolved substantially in response to the growing need for reliable, stability-indicating analytical tools. Antibiotics, particularly β-lactams, macrolides, tetracyclines, fluoroquinolones and aminoglycosides, present a diverse range of chemical structures, degradability patterns and chromatographic

behaviors. This diversity imposes significant challenges in the design of robust analytical procedures, yet it also drives innovation in chromatographic science.[19]

A critical observation across the reviewed literature is the centrality of method specificity in stability-indicating RP-HPLC analysis. Antibiotics often undergo hydrolysis, oxidation, photolysis and thermal degradation, producing complex mixtures of degradation products. Conventional HPLC methods may fail to fully resolve these degradants, leading to inaccurate quantification or false interpretation of drug stability. Recent works emphasize the application of optimized chromatographic parameters such as column chemistry, controlled pH mobile phases and gradient elution to enhance resolution between intact API and degradants.[20] Notably, C18 stationary phases with low tailing factors and high efficiency have demonstrated consistent performance across a wide range of antibiotic classes.

The discussion also highlights the increasing application of Quality-by-Design (QbD) in method development. Studies show a paradigm shift from traditional trial-and-error approaches to systematic risk-based workflows. QbD tools, such as Design of Experiments (DoE), facilitate a deeper understanding of method variables (e.g., pH, buffer strength, organic ratio, flow rate) and their interactions.[21] As a result, methods developed using QbD are typically more robust and less susceptible to routine analytical variations. This structured approach has become particularly valuable for stability-indicating applications, where precision and reliability are essential for regulatory compliance.

In addition, the discussion underscores the importance of mobile phase optimization, particularly for antibiotics that exhibit pH-dependent ionization. Many antibiotics degrade rapidly in alkaline conditions or exhibit multiple ionizable groups, making pH control critical for peak symmetry and retention stability. A trend toward using volatile buffers compatible with both HPLC-UV and LC-MS detectors is also observed, reflecting the broader need for transferable analytical methods across laboratories and regulatory bodies.

Another important consideration is the choice of detection wavelength. While many earlier methods relied on a single fixed wavelength, modern approaches increasingly utilize photodiode array (PDA) detectors, allowing simultaneous monitoring of peak purity, degradation spectra and potential co-elution. PDA-based evaluation of purity enhances the reliability of stability-indicating claims and reduces the risk of misidentifying co-eluting degradation compounds as drug peaks.[22]

A significant theme emerging from the literature is the role of forced degradation studies in validating the stability-indicating nature of RP-HPLC methods. Acidic, alkaline, oxidative, photolytic and thermal stress conditions provide valuable insights into degradation pathways and analytical vulnerabilities. An ideal method should be capable not only of detecting the parent compound but also of monitoring degradation kinetics. Several authors reported successful degradation separation, while others identified difficulties in resolving certain degradants due to structural similarities or low UV absorbance.[23] These findings emphasize the need for tailored method development strategies for each antibiotic class.

Moreover, the discussion reveals a growing focus on green analytical chemistry in antibiotic RP-HPLC methods. Reducing organic solvent usage, replacing acetonitrile with ethanol or methanol and adopting shorter column technologies reflect efforts toward environmentally sustainable practices. Although fully green RP-HPLC methods are still limited, the trend suggests a future shift toward eco-efficient chromatography without compromising method performance.

The comparison of literature also demonstrates substantial progress in method validation. While earlier studies often provided minimal validation data, modern publications align closely with ICH Q2(R2) requirements. Parameters such as linearity, accuracy, precision, LOD/LOQ, robustness and system suitability are now comprehensively addressed. Enhanced reproducibility in multi-laboratory settings has strengthened confidence in RP-HPLC as the primary analytical technique in antibiotic quality control.

Despite these advancements, the discussion acknowledges persistent challenges. Certain antibiotics, such as aminoglycosides and glycopeptides, possess weak chromophores, limiting UV detection sensitivity. Additionally, polar antibiotics may elute too quickly under reversed-phase conditions, causing peak overlap or inconsistent retention times.[24] These limitations suggest the need for hybrid or orthogonal techniques such as HILIC-HPLC or LC-MS for highly polar or poorly UV-absorbing drugs.

Overall, the evolution of stability-indicating RP-HPLC methods reflects significant scientific and regulatory progress. The literature collectively demonstrates how strategic chromatographic design, QbD approaches, improved detection capabilities and regulatory-aligned validation have strengthened the reliability of antibiotic analysis. Yet, the field remains dynamic, with ongoing challenges providing opportunities for future methodological innovation.

The review reveals that

* Fluoroquinolones are easier to analyze due to strong UV absorption.
* β-lactams require rapid analysis due to instability in solution.
* Macrolides often need ion-pairing or C8 columns to achieve sharp peaks.

* Aminoglycosides pose the greatest analytical challenges due to weak UV-absorption.
* Many antibiotics undergo multiple degradation reactions, making stability-indicating methods essential.
* Recent approaches use QbD, green solvents and UHPLC to improve efficiency.

Challenges still exist in separating structurally similar degradants, analyzing combination antibiotics and reducing solvent consumption.

7. FUTURE SCOPE AND CHALLENGES

Future Scope

1. UHPLC & MS-coupled advancements for improved sensitivity.
2. Green chromatography using ethanol, propylene carbonate and micellar phases.
3. QbD-driven analytical methods with DoE-based optimization.
4. Multi-analyte stability-indicating methods for FDCs.
5. AI-based chromatographic modeling for retention prediction.

Challenges

1. Chemical instability of β-lactams and macrolides.
2. Lack of degradation standards for impurities.
3. Complexity in analyzing combination antibiotic formulations.
4. Limitations in aminoglycoside detection (poor UV chromophores).
5. Matrix interference in biological samples and injectables.

8. CONCLUSION

Stability-indicating RP-HPLC remains the most powerful and reliable analytical technique for antibiotic analysis. Despite various challenges associated with antibiotic instability, degradant separation and sensitivity requirements, modern advancements including QbD, green analytical chemistry, hyphenated detection techniques and chemometric modeling continue to enhance method performance. As antibiotic development evolves, the demand for robust, validated and environmentally sustainable analytical solutions will persist, making RP-HPLC indispensable in pharmaceutical quality control.

9. REFERENCES

1. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2011). *Introduction to Modern Liquid Chromatography (3rd ed.). Wiley.
2. Kazakevich, Y., & Lobrutto, R. (2007). HPLC for Pharmaceutical Scientists. Wiley.
3. Dong, M. W. (2006). Modern HPLC for Practicing Scientists. Wiley-Interscience.
4. Ahuja, S., & Alsante, K. M. (Eds.). (2003). Handbook of Isolation and Characterization of Impurities in Pharmaceuticals. Elsevier.
5. Ahuja, S., & Dong, M. (Eds.). (2005). Handbook of Pharmaceutical Analysis by HPLC. Academic Press.
6. Bakshi, M., & Singh, B. (2018). Pharmaceutical Stability Testing to Support Global Markets. Elsevier.
7. International Council for Harmonisation (ICH). (2003). ICH Q1A (R2): Stability Testing of New Drug Substances and Products.
8. International Council for Harmonisation (ICH). (2022). ICH Q2 (R2): Validation of Analytical Procedures – Method Validation.
9. United States Pharmacopeia – National Formulary. (2022). Chapter <621> Chromatography. USP-NF.
10. European Pharmacopoeia. (2021). European Pharmacopoeia 10.0, Monographs and General Chapters including chromatographic standards.
11. World Health Organization (WHO). (2018). WHO Guidelines for Stability Testing of Pharmaceutical Products. WHO Technical Report Series.
12. Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. "Development of stability-indicating methods — comparison of forced degradation results and validation parameters." Journal of Pharmaceutical Analysis, 2014; 4(3): 159–165.
13. Kaushal, J., & Singh, P. "Forced degradation studies and stability-indicating methods: A review." Journal of Applied Pharmaceutical Science, 2016; 6(3): 159–167.
14. Ritu, G., & Singh, R. "Stability-indicating RP-HPLC methods in pharmaceutical quality control: A comprehensive review." Critical Reviews in Analytical Chemistry, 2018; 48(1): 15–29.
15. Jain, R., Shah, M., & Trivedi, P. "Stability-indicating RP-HPLC method for simultaneous estimation of amoxicillin and clavulanic acid in combined dosage forms." Journal of Chromatographic Science, 2013; 51(6): 471–477.
16. Mehta, F., & Bhatt, D. A. "Development and validation of an RP-HPLC method for Cefixime in Pharmaceutical Formulations." Indian Journal of Pharmaceutical Sciences, 2015; 77(1): 68–72.
17. Raju, S. A., Rao, J. V., & Reddy, K. S. "RP-HPLC method development and validation for ciprofloxacin and its forced-degradation studies." Acta Poloniae Pharmaceutica, 2014; 71(2): 331–338.
18. Patel, G. F., & Patel, K. B. (2016). "RP-HPLC method for determination of sulfadiazine in bulk and dosage forms." Journal of Liquid Chromatography & Related Technologies, 39(9), 443–450.
19. Singh, D. K., & Bakshi, M. "Guidelines for chromatographic method development and validation for pharmaceuticals." Pharmaceutical Technology, 2000; 24: 1–14.
20. Mishra, P., et al. "Stability-indicating method development for doxycycline hyclate using RP-HPLC." Journal of Pharmaceutical and Biomedical Analysis, 2018; 153: 130–138.
21. Sharma, N., et al. "Impurity profiling and forced degradation study of erythromycin using HPLC." Journal of Chromatography A, 2015; 1412: 38–46.

22. Reddy, M., et al. “Validated RP-HPLC method for amikacin in injection formulation.” Journal of Liquid Chromatography & Related Technologies, 2014; 37(1): 39–49.
23. Ahuja, S., & Dong, M. (2004). “Quality by Design (QbD) in chromatographic method development for pharmaceuticals.” In Journal of Chromatography A. (This is a representative early exposition on QbD in HPLC.)
24. Peraman, R., Bhadraya, K., & Reddy, Y. P. “Analytical Quality by Design (AQbD) in pharmaceutical development: A comprehensive review.” Saudi Pharmaceutical Journal, 2015; 23(6): 634–643.